

DIANA BIOTECHNOLOGIES

Kinase Inhibitor Profiling

Service without compromises

DIANA Inhibitor Profiling: Superior service

Compound Selection


Compound **Shipment**


Compound **Profiling**

Receive **Results**









Pick your compounds and decide whether you want to profile them against one of the **predefined kinase panels** or if you prefer our **custom selection service**.

Send us your compounds and we will analyze them right away.

If you need any support, we will be in close contact with you.

Thanks to proprietary **DIANA Technology** the compound profiling will yield **quantitative inhibition potency data** in form of binding constants (Kd).

Turnaround time for your results is **7–14 business days**, varying with order complexity.

We are happy to help you interpret the data whenever needed.

Introduction of DIANA technology

Competitive Binding Assay

DIANA assay measures potency of tested compound as function of its competition with **DIANA probe**.

The assay delivers **true binding constants** (Kd) of test compound.

qPCR Readout


The amount of displaced **DIANA probe** is quantitatively determined by qPCR.

qPCR readout ensures high dynamic range and enables calculation of Kd from a single measurement.

Superior to KINOMEscan™

Both methods use solid phase assay setup with qPCR readout and yield **highly similar results** for most kinases.

DIANA's more advanced setup enable the use of **recombinant kinases** with posttranslational modifications instead of simpler phage constructs.



TECHNOLOGY INTRODUCTION DIANA BIOTECHNOLOGIES 4

UNIQUE features of DIANA ensure BEST in-class service



Quantitative data

DIANA assay provides true binding constants (Kd) from each measurement



Robustness

Compatibility with 10% DMSO improves precision with poorly soluble compounds



Ultra-low interferences

Assay format and PCR read-out ensures minimal chance of compound interference



Internal quality control

Binding potency of known inhibitor determined for each tested kinase in each run



Get more for your price

Quantitative potency data for the price of relative potency data



Rapid turnaround time

7 business days for standard and 14 business days for complex services



Flexible customization

Assemble your own kinase panel for comparable price as our focused panels



Whole kinome coverage

Our kinase assay portfolio covers all kinase groups within human kinome

Accelerate your projects – get quantitative potency data from the start!

Our Kinase Profiling Services

	DIANA Kinase Panel	DIANA TK Panel	DIANA CDK Panel	Custom selection			
	Panel of kinases covering entire kinome	Panel of tyrosine kinases (TK)	Panel of cyclin-dependent kinases (CDK)	Customize kinase panel for your assay			
Number of kinases	170*	68	24	1			
Price in EUR per 1 compound	2500	1360	480	25** 7 business days			
Turnaround time***	14 business days	7 business days	7 business days				
Result	Dissociation constant (Kd)						

*The stated number is approximate. The precise number of available kinase assays can be found in our kinase assay list at our websites (QR link available in this presentation).

**Minimal Order Quantity for Custom Selection service is 500 EUR.

***Counts from the day compounds are delivered to our testing facility.

For complex orders the turnaround time can be extended to 14/21 business days, respectively.

DIANA Kinase Panel

MORE THAN 170 KINASE ASSAYS


DIANA Kinase Panel representatively covers whole kinome (highlighted as red dots in the kinome tree)

ONLY PRODUCT ON THE MARKET...


...that provides quantitative potency data on a whole-kinome scale.

Follow this link or scan QR code to get current kinase assays list:





Staurosporine inhibition profile determined by DIANA Kinase panel compared with reference data on 80 selected kinases



DIANA CDK Panel


24 CDK/CYCLIN PAIRS AVAILABLE

Cyclin Dependent Kinases (CDKs) are involved in essential cellular processes such as cell cycle and transcription.


CDKs are regulated by their binding partners, cyclins.

Cell Cycle CDKs/cyclins	CDK1 CycB1	CDK2 CycA2	CDK3 CycE1	CDK4 CycD1	CDK4 CycD2	CDK4 CycD3	CDK6 CycD1	CDK6 CycD3	
Transcriptional CDKs/cyclins	CDK7 CycH1	CDK7 CycH1 MNAT1	CDK8 CycC	CDK9 CycT1	CDK9 CycT2	CDK10 CycQ	CDK11A	CDK12 CycK	CDK13 CycK
Atypical CDKs/cyclins	CDK5 p25	CDK5 p35	CDK14 CycY	CDK16 CycY	CDK17 CycY	CDK18 CycY	CDK19 CycC		

Kd values calculated from 5-6 concentrations of 3 different inhibitors for CDK3/cycE1 are highly consistent



Comparative analysis of inhibition profile of Staurosporine



DIANA TK Panel

68 TYROSINE KINASES AVAILABLE


Tyrosine kinases are key drivers of cancer and other diseases with over 20 FDA-approved drugs on the market.

DIANA TK Panel covers over 70% of all human tyrosine kinases.


Follow this link or scan QR code to get current TK assays list:



Kd values calculated from 6-9 concentrations of 3 different inhibitors for EPHA4 are highly consistent







*Inhibition potency of Staurosporine against EPHB3 in Davis et al. study was not determined (i.e. it was higher than 10000nM which is assay detection limit)

Identify new inhibitors for your kinase with us

High-Throughput Screening (HTS) service is available for all kinases listed in our panels. Custom development for other kinases possible.

Technical parameters

Excellent Z' factor (commonly Z' > 0.8);

Close to zero false positivity rate.


In-house small compound libraries

- 1. Drug-like Diversity Set app. 120 000 compounds (mid MW and logP).
- 2. Lead-like Diversity Set app. 10 000 compounds (low MW and logP).
- 3. FDA library 2823 compounds.
- 4. Kinase Inhibitor Library 1930 compounds.

Pricing options

Low kinase consumption → highly compatible pricing;

Pricing of the service is quoted individually based on the customer demands.



Who we are?

YEARS ON THE MARKET


We are European biotech company founded in 2018 in Prague as academic spin-off focusing on utilization of DIANA technology in Drug Discovery programs.

MILLION EUR **IN REVENUE**

From 2020 to 2022 we switched towards development of PCR-based diagnostic of COVID-19 with big commercial success: more than 7.5 million PCR tests sold.

SEGMENTS AND SERVICES Currently, we are a diversified biotech company that provides innovative solutions in drug discovery, monoclonal antibody production, life science reagents, and PCR diagnostics.





Contact us

Contact our global experts to discover how we can help you realize your vision:



sales@dianabiotech.com




www.dianabiotech.com



DIANA Biotechnologies, a.s. Průmyslová 596 252 50 Vestec Czech Republic





Head of Drug Discovery

To learn more about Drug Discovery services, contact me via



jan.tykvart@dianabiotech.com



Lucia Bialesova

Business Development

To place the order or get the price quote, contact me via



lucia.bialesova@dianabiotech.com



Alena Uvizl

Technology Development

To learn more about technology of our service, contact me via



alena.uvizl@dianabiotech.com